Literature DB >> 20685582

Current status of postoperative radiation for non-small-cell lung cancer.

Mert Saynak1, Daniel S Higginson, David E Morris, Lawrence B Marks.   

Abstract

Radiation therapy can increase local control and potentially improve survival in patients who have had resection for lung cancer. However, radiation therapy also has the potential to cause serious toxicity and should not be indiscriminately delivered. The PORT meta-analysis clearly illustrated the potential toxic effects of postoperative radiotherapy (PORT). Modern three-dimensional radiation treatment planning facilitates the design of treatment fields that more conformally treat the site(s) at risk, and this appears, based on limited data, to improve the therapeutic ratio of PORT. Moreover, systemic and local therapies are likely synergistic, and thus improvements in systemic staging and treatment may increase the ability of local therapies to improve overall survival. Therefore, a reassessment of the utility of postoperative radiation therapy using limited fields and modern techniques is warranted. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20685582     DOI: 10.1016/j.semradonc.2010.01.008

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  7 in total

Review 1.  Prediction of radiation pneumonitis in lung cancer patients: a systematic review.

Authors:  Xiao-Jing Zhang; Jian-Guo Sun; Jie Sun; Hua Ming; Xin-Xin Wang; Lei Wu; Zheng-Tang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-29       Impact factor: 4.553

Review 2.  Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  A Gómez; J A González; F Couñago; C Vallejo; F Casas; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2015-08-18       Impact factor: 3.405

Review 3.  Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC).

Authors:  Bojan Zaric; Vladimir Stojsic; Aleksandar Tepavac; Tatjana Sarcev; Paul Zarogoulidis; Kaid Darwiche; Kosmas Tsakiridis; Ilias Karapantzos; Georgios Kesisis; Ioanna Kougioumtzi; Nikolaos Katsikogiannis; Nikolaos Machairiotis; Aikaterini Stylianaki; Christophoros N Foroulis; Konstantinos Zarogoulidis; Branislav Perin
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

4.  Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancer.

Authors:  Xuquan Jing; Xue Meng; Xindong Sun; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-02-19       Impact factor: 4.147

Review 5.  Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment.

Authors:  Debora Brascia; Giulia De Iaco; Marcella Schiavone; Teodora Panza; Francesca Signore; Alessandro Geronimo; Doroty Sampietro; Michele Montrone; Domenico Galetta; Giuseppe Marulli
Journal:  Cancers (Basel)       Date:  2020-07-25       Impact factor: 6.639

6.  Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy.

Authors:  Chengcheng Fan; Shugeng Gao; Zhouguang Hui; Jun Liang; Jima Lv; Xiaozhen Wang; Jie He; Luhua Wang
Journal:  Radiat Oncol       Date:  2013-12-09       Impact factor: 3.481

7.  Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis.

Authors:  Vasileios Askoxylakis; Judith Tanner; Jutta Kappes; Hans Hoffmann; Nils H Nicolay; Harald Rief; Juergen Debus; Michael Thomas; Marc Bischof
Journal:  BMC Cancer       Date:  2014-08-07       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.